Borrmann Type IV Gastric Cancer: Focus on the Role of Gastrectomy

Chengcai Liang,Guoming Chen,Baiwei Zhao,Haibo Qiu,Wei Li,Xiaowei Sun,Zhiwei Zhou,Yingbo Chen
DOI: https://doi.org/10.1007/s11605-019-04236-7
2019-01-01
Journal of Gastrointestinal Surgery
Abstract:Objectives The benefits of curative or palliative gastrectomy for Borrmann type IV (B-IV) gastric cancer remain controversial. This study was conducted to investigate whether or not gastrectomy could benefit prognosis of patients with Borrmann type IV gastric cancer. Material and Methods A cohort of 469 B-IV gastric cancer patients from January 2001 to September 2017 was retrospectively reviewed. Survival analysis was used to investigate the prognosis of patients with or without gastrectomy. Results Among this cohort, the average age was 55 years and the median follow-up time was 12 months. One hundred and forty-six (31%) patients underwent curative resection, 187 (40%) patients underwent palliative resection, and the remaining 136 (29%) patients were judged unresectable. During the follow-up, a total of 294 (63%) patients died. Cox multivariate analysis showed that Tumor Node Metastasis (TNM) stage ( p = 0.002), grade ( p = 0.033), and gastrectomy ( p < 0.001) were independent predictors of overall survival. Kaplan–Meier analysis revealed that, no matter in total group or subgroup stratified by tumor stage and grade, overall survival rates at 1 year, 2 years, and 5 years in patients with palliative resection were significantly worse than those in patients with curative resection (all p < 0.05), but significantly better than those in patients with no resection (all p < 0.05). Conclusions Curative or palliative gastrectomy could increase the survival rate for B-IV gastric cancer patients. In the absence of alternative effective therapies, surgical resection remains a choice of improved survival or potential cure for B-IV gastric cancer.
What problem does this paper attempt to address?